{"id":"W2590047801","doi":"10.1200/jco.2014.32.4_suppl.443","title":"Dovitinib in first-line renal cell carcinoma: An investigation into tumour gene status and correlation with efficacy: A phase II clinical trial.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Renal cell carcinoma; Gastroenterology; Adverse effect; Phases of clinical research; Performance status; Progression-free survival; Surgery; Abdominal pain; Oncology; Clinical trial; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001691944,0.0009959585,0.001763785,0.0004327738,0.0002560155,0.001052003,0.0007311162,0.001253106,0.002192185],"category_scores_gemma":[0.001088558,0.0004161266,0.001058621,0.0005682302,0.0006988518,0.0005161653,0.0002275891,0.001730527,0.0004397704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009422358,"about_ca_system_score_gemma":0.001054127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006874733,"about_ca_topic_score_gemma":0.001637014,"domain_scores_codex":[0.9996481,0.0001494994,0.0000202559,0.00006281738,0.00005180786,0.00006745095],"domain_scores_gemma":[0.9991606,0.000204896,0.0002132789,0.00006307614,0.0000451085,0.0003129148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7951552,0.03967411,0.02514436,0.001115112,0.001430473,0.0002580158,0.0002093064,0.002010885,0.03724824,0.0001985886,0.002386458,0.0951691],"study_design_scores_gemma":[0.6136302,0.3283005,0.04488035,0.00004592981,0.0008653295,0.0005482955,0.00004853723,0.002764416,0.006951013,0.0001264558,0.001791608,0.00004728012],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960038,0.001841257,0.0001338924,0.0002082194,0.00004244629,0.000585371,0.0005260906,0.00004968165,0.0006092264],"genre_scores_gemma":[0.9954286,0.001025352,0.0005007677,0.0002920569,0.00008912366,0.0005493669,0.001205064,0.00001160743,0.000898156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002192185,"threshold_uncertainty_score":0.008947909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1265764195683436,"score_gpt":0.434838953061354,"score_spread":0.3082625334930104,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}